Press Releases
September 3, 2009
Stratatech Launches StrataTest® Human Skin Model to European Market
Full-thickness human skin equivalent exhibits characteristics of native human skin
MADISON, Wis., September 3, 2009 – Stratatech Corp., a privately-held regenerative medicine company, today announced that it will launch its StrataTest® full-thickness human skin model to the European market at EUROTOX 2009, the annual meeting of the Federation of European Toxicologists and the European Societies of Toxicology. This year’s meeting is being held in Dresden, Germany, Sept. 13-16.
Composed of both an epidermis and a dermis, the StrataTest® human skin model displays the physical, chemical and histological characteristics of native human skin. The tissue is readily available and is supplied in an easy-to-use, 24-well format for consumer product testing, drug discovery and toxicity screening.
The StrataTest® human skin model, which is intended for research use only and is in early-state ECVAM (European Centre for the Validation of Alternative Methods) validation, is manufactured using Stratatech’s proprietary and clinically-tested NIKS® human keratinocytes. NIKS® cells, which have been shown to be pathogen-free and non-tumorigenic, consistently produce a fully-stratified, multi-layered human skin substitute tissue in each well of the StrataTest® test plate. Each tissue grows as new, native human skin does, replicating its structure and function.
The StrataTest® product will be featured at the company’s booth at the scientific and commercial exhibition (no. 34 on the Conference Level) being held in conjunction with EUROTOX 2009. The product also will be exhibited at the Organotypic Tissue Culture Substance Evaluation meeting, which is being held Sept. 22-25, in Potsdam, Germany.
“Stratatech is very pleased to launch our StrataTest® human skin model,” said Lynn Allen-Hoffmann, Ph.D., president, chief executive and chief scientific officer of Stratatech. “StrataTest® provides what we believe is a superior, cost-effective skin model for consumer product, drug discovery and other toxicity testing applications. The human skin equivalent supplied in our 24-well StrataTest® plate offers not only an enhanced, high-quality in vitro testing model, it enables better prediction of in vivo biological response.”
About Stratatech Corp.
Stratatech Corp. is a Madison, Wis.-based a regenerative medicine company focused on the development and commercialization of cell-based, tissue-engineered skin substitute products for therapeutic and research applications. The company’s valuable product pipeline, based on its patented NIKS® human keratinocytes, is comprised of the next generation of skin substitute products that have numerous advantages over tissue-engineered products generated from human skin sourced by conventional means. For more information about Stratatech, its technology and product pipeline, please visit the company’s website at www.stratatechcorp.com.